ARTICLE | Clinical News
Velaglucerase alfa regulatory update
December 7, 2009 8:00 AM UTC
Shire submitted an MAA to EMEA for velaglucerase alfa to treat Type 1 Gaucher's disease. The agency's CHMP accepted the company's request for an accelerated assessment, which shortens the review time ...